thymoproteasome-expressing mesenchymal stromal cells

Thymoproteasome-expressing mesenchymal stromal cells (MSC-TPr) are an experimental cell-based immunotherapy and cellular vaccine developed by CELL Technologies and IntelliStem Technologies. These mesenchymal stromal cells (MSCs) are genetically engineered to express the thymoproteasome (TPr) complex, a specialized proteasome typically found in cortical thymic epithelial cells that is essential for the positive selection of CD8+ T-cells. In a cancer context, MSC-TPr acts as an immune-modifying agent that, upon administration, recruits myeloid cells—specifically dendritic cells and macrophages. The dendritic cells cross-prime endogenous T-cells with tumor antigens, triggering a potent and specific CD8+ T-cell-mediated anti-tumor immune response. Preclinical studies in lymphoma and melanoma models have demonstrated that this approach can lead to complete protection and tumor regression, particularly when inhibitory macrophage populations are managed.

Other names

thymoproteasome-expressing mesenchymal stem cellsimmune-modifying MSCs